Primelink Biotherapeutics (Shenzhen) Co. Ltd. has discovered molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Discoidin domain receptor tyrosine kinase 1 (DDR1) contributes to tumor progression by promoting the alignment and densification of collagen fibers within the extracellular matrix (ECM), thereby facilitating the development of an immune-excluded tumor microenvironment (TME).
Polycystic ovary syndrome is a common endocrine disorder in women of reproductive age and characterized by obesity, insulin resistance and renal injury.
Dana Farber Cancer Institute Inc. and Stanford University have patented new molecular glue degraders comprising cereblon (CRBN) binding moiety acting as casein kinase 1 isoform α and/or wee1-like protein kinase (Wee1) degradation inducers reported to be useful for the treatment of cancer.
Amphista Therapeutics Ltd. has identified compounds acting as bromodomain-containing protein 9 (BRD9) degradation inducers reported to be useful for the treatment of cancer.
Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. has disclosed bifunctional compounds acting as RAC serine/threonine-protein kinase (AKT; PKB) degraders reported to be useful for the treatment of cancer.
Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and respiratory disorders.
Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting moiety acting as IKZF1 degradation inducers potentially useful for the treatment of cancer, autoimmune disease, neurodegeneration and inflammatory disorders.
RSS
